Sunday, October 25, 2020

Low-cost chip to detect COVID-19 antibodies developed

Must Read

T.S reports 978 fresh COVID cases, overall tally rises to 2,31,252

Hyderabad: Telangana reported 978 new COVID-19 cases, taking the overall tally to 2,31,252, while four more deaths pushed the...

Samsung Chairman Lee Kun-hee passes away at 78

Seoul, Oct 25 : Lee Kun-hee, the Chairman of South Korea’s techn giant Samsung Electronics, died at the age...

Bharat Biotech to conduct Phase-3 trials on 26,000 volunteers

Hyderabad: BharatBiotech, which is into developing Covaxin, a vaccine candidate for COVID-19, on Friday said it has successfully completed...

Tokyo: To fight against Covid-19, Japanese scientists have developed a rapid, reliable and low-cost antibody test, that uses portable lab-on-a-chip technology to accurately measure the concentration of antibodies present in diluted blood plasma.

Previous studies have found that Covid-19 antibodies, or proteins produced by the immune system to neutralise the virus, are present in the later stages of infection and can linger in the blood after the infection has cleared, allowing previously infected individuals to be identified, the study published in the journal Biosensors and Bioelectronics said.

Antibody tests are, thus, an important means of determining the full spread of the coronavirus – information that is crucial to guide public health policies, it said.

“Many existing platforms for antibody tests are accurate and reliable, but they are costly and need to be carried out in a lab by trained operators. This means that it can take hours, or even days, to obtain results,” said study author Riccardo Funari from the Okinawa Institute of Science and Technology Graduate University (OIST).

The researchers avoided this trade-off between accuracy and accessibility by developing an alternative antibody testing platform that combines powerful light-sensing technology with a microfluidic chip.

The chip provides results within 30 minutes and is highly sensitive, detecting even the lowest clinically-relevant antibody concentration.

Each chip is cheap to manufacture and negates the need for a lab or trained operators, increasing the feasibility of nation-wide testing.

And there’s another distinctive advantage of this newly-developed platform.

“The test doesn’t just detect whether the antibodies are present or absent – it also provides information about the number of antibodies produced by the immune system. In other words, it’s quantitative,” said study author Amy Shen.

The antibody testing platform consists of a microfluidic chip which is integrated with a fibre optic light probe. The chip itself is made from a gold-covered glass slide with an embedded microfluidic channel.

Using an electric voltage, the team fabricated tens of thousands of tiny spiky gold structures, each one smaller than the wavelength of light, on a glass slide.

The researchers then modified these gold nano spikes by attaching a fragment of the SARS-CoV-2 spike protein. This protein is crucial for helping the coronavirus infect cells and causes a strong reaction from an infected person’s immune system.

In this proof-of-concept study, the scientists demonstrated the principle behind how the test detects antibodies by using artificial human plasma sample spiked with Covid-19 antibodies that are specific to the spike protein.

Using a syringe pump, the sample is drawn through the chip. As the plasma flows past the protein-coated gold nano spikes, the antibodies bind to the spike protein fragments. This binding event is then detected by the fibre optic light probe.

“The detection principle is simple but powerful,” said the study authors wrote.

Subscribe us on The Siasat Daily - Google News

Latest News

T.S reports 978 fresh COVID cases, overall tally rises to 2,31,252

Hyderabad: Telangana reported 978 new COVID-19 cases, taking the overall tally to 2,31,252, while...

Samsung Chairman Lee Kun-hee passes away at 78

Seoul, Oct 25 : Lee Kun-hee, the Chairman of South Korea’s techn giant Samsung Electronics, died at the age of 78 here on Sunday,...

Bharat Biotech to conduct Phase-3 trials on 26,000 volunteers

Hyderabad: BharatBiotech, which is into developing Covaxin, a vaccine candidate for COVID-19, on Friday said it has successfully completed an interim analysis of Phase...

Rs 50 crores to be spent on the repair work on roads in Alwal

Alwal: The incessant rains in Hyderabad since the past week have made lives miserable in the city, especially for people living in the low-lying...

RR keen to brighten playoff chances vs Mumbai (IPL Match Preview 45)

Abu Dhabi, Oct 24 (IANS/GloFans) The 2008 Indian Premier league (IPL) champions, Rajasthan Royals (RR), may be placed at the seventh spot at the...

More Articles Like This